CB2R/FAAH modulator-3
CAS No. 2876918-67-9
CB2R/FAAH modulator-3( —— )
Catalog No. M35955 CAS No. 2876918-67-9
CB2R/FAAH modulator-3 (compound 27) is a modulator targeting CB2R and FAAH, acting as a CB2R agonist with a Ki value of 20.1 nM and a CB1R agonist with a Ki value of 67.6 nM, while inhibiting FAAH with an IC50 value of 3.4 μM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 33 | In Stock |
|
| 5MG | 29 | In Stock |
|
| 10MG | 50 | In Stock |
|
| 25MG | 103 | In Stock |
|
| 50MG | 152 | In Stock |
|
| 100MG | 230 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCB2R/FAAH modulator-3
-
NoteResearch use only, not for human use.
-
Brief DescriptionCB2R/FAAH modulator-3 (compound 27) is a modulator targeting CB2R and FAAH, acting as a CB2R agonist with a Ki value of 20.1 nM and a CB1R agonist with a Ki value of 67.6 nM, while inhibiting FAAH with an IC50 value of 3.4 μM.
-
DescriptionCB2R/FAAH modulator-3 (compound 27) is a dual targeting modulator that acts as a CB2R agonist and FAAH inhibitor. The Ki values for CB2R/FAAH modulator-3 are 20.1 and 67.6 nM for CB2R and CB1R, respectively, and the IC50 value for FAAH is 3.4 μM. CB2R/FAAH modulator-3 can be used in studies related to cancer, deleterious inflammatory cascades occurring in neurodegenerative diseases, and COVID-19 infection.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetCannabinoid Receptor
-
RecptorCannabinoid Receptor | FAAH
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2876918-67-9
-
Formula Weight341.49
-
Molecular FormulaC22H31NO2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (146.42 mM; Ultrasonic )
-
SMILESCCCCCOc1ccccc1C(=O)NC12CC3CC(CC(C3)C1)C2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
CB1 antagonist 2
CB1 antagonist 2 is caimabinoid 1 (CB1) antagonist extracted from patent WO2016184310A1, compound 3. Which inhibits CB1 in vivo with an IC50 of 25.5 nM.
-
Otenabant
A potent, and selective CB1 receptor antagonist with Ki of 0.7 nM/0.12 nM in binding and functional assays respectively; has low affinity (Ki=7600 nM) for human CB2 receptors; reverses cannabinoid agonist mediated responses, reduces food intake, and increases energy expenditure and fat oxidation in rodents.ObesityPhase 3 Discontinued
-
CP-724714
CP-724714 is an effective and selective HER2/ErbB2 inhibitor (IC50: 10 nM), >640-fold selectivity against EGFR, Abl, InsR, PDGFR, IRG-1R, Src, VEGFR2, c-Met etc.
Cart
sales@molnova.com